Nonetheless, research has found that its weakness may very well be its strength. -Studies suggest that when the lower-potency estrogen, estriol, is administered topically, it does not increase the risk of hormone-dependent cancers of the breast or endometrium (uterine lining).1-3 However, having weaker estrogenic effects does not mean that estriol has none of the benefits that come with more potent estrogens.
Daraasaduhu waxay soo jeedinayaan in marka hawo-darrada hoose ee estrogen, estriol, loo isticmaalo si taxadar leh, ma kordhinayso halista kansarka hormoon-ka ah ee naaska ama endometrium (qoorta uterine).1-3 Si kastaba ha noqotee, saamaynta daciifinta estrogenic micnaheedu maaha in estriol ma laha wax faa'iido leh oo la yimaada estrogens xooggan.